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non-coverage decision. Of the positive decisions, 22 were associated with an economic 
evaluation that estimated the medical intervention to be dominant (costs less and more
effective than the alternative), 8 with an incremental cost-effectiveness ratio (ICER)
of less than $50,000, 8 with an ICER greater than $50,000 but less than $100,000, 
and 8 with an ICER greater than $100,000 (2008 USD). In four of the positive cover-
age decisions the intervention was dominated (costs more and was less effective than 
the alternative). Of the non-coverage decisions, 3 interventions were estimated to be
dominant, 6 were associated with an ICER less than $30,000, one with an ICER of 
approximately $200,000, and four were dominated. Fourteen decision memos cited 
or discussed cost-effectiveness information. CONCLUSIONS: CMS is covering a
number of interventions that do not appear to be cost-effective by traditional stan-
dards. While we identiﬁ ed several instances where cost-effectiveness evidence was cited 
in NCDs, we found no clear evidence of an implicit constant ﬁ xed cost-effectiveness 
threshold.
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OUT OF POCKET PSYCHOTROPIC PRESCRIPTION BURDEN ON
ELDERLY MEDICARE BENEFICIARIES BEFORE AND AFTER THE
IMPLEMENTATION OF MEDICARE PART D
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OBJECTIVES: To examine the out of pocket spending on psychotropic medications 
by elderly Medicare beneﬁ ciaries before and after the implementation of Medicare
Part D. METHODS: The effect of Part D was measured using 2005–2006 pharmacy
claims data from one of the largest retail pharmacy chains in the United States. The 
psychotropic medications examined in this study included antidepressants, antipsy-
chotics benzodiazepines and barbiturates. In addition to evaluating overall out of 
pocket burden in 2005 and 2006, the study examined out of pocket burden among 
Medicare-Medicaid dual eligible beneﬁ ciaries, non-dual Part D enrollees, and those
who did not enroll in Medicare Part D. The out of pocket burden was calculated as
a percentage of total pharmacy reimbursement involving elderly persons 65 years or 
older. RESULTS: The proportion of out of pocket expenditures in total pharmacy 
reimbursement dropped 7.62% (from 40.43% to 32.81%) for antidepressants, 6.24% 
for antipsychotics (from 27.82% to 21.58%), but increased 12.15% for benzodiaze-
pines (from 62.64% to 74.79%), and 9% (from 71.96% to 80.56%) for barbiturates.
Dual eligible beneﬁ ciaries were the group most severely affected by the policy change. 
For dual eligible beneﬁ ciaries who were on any of the four drug categories, their yearly
out of pocket expense increased extensively. The most dramatic change was observed 
in dual eligibles using benzodiazepines. Their out of pocket expenditure increased by
around 12 folds from 2005 to 2006. Non-dual Part D enrollees beneﬁ ted the most
from the new drug policy. The most signiﬁ cant cost saving was found in non-dual Part 
D enrollees who were on antidepressants (from 62.23% to 32.97%) and antipsychot-
ics (from 55.24% to 38.30%). CONCLUSIONS: The implementation of Part D was 
associated with reduced out of pocket psychotropic prescription burden on non-dual
Part D enrollees, however, out-of –pocket burden on the dual eligible beneﬁ ciaries
severely increased.
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OBJECTIVES: We compared patient preference and satisfaction between two osteo-
porosis medications: alendronate (ALN 70 mg tablets) taken orally once weekly (QW)
and denosumab (DMAb 60 mg; investigational agent) injected subcutaneously (SC) 
every 6 months (Q6M). METHODS: Preference and satisfaction were evaluated as
part of a phase 3, double-blind, double-dummy study to determine the effects of tran-
sitioning subjects from ALN to DMAb. Postmenopausal women q55 with a lumbar 
spine or total hip T-score a2.0 and q4.0 who were receiving ALN therapy for q6 
months were eligible. After a 1-month ALN run-in phase, subjects were randomized
to treatment with continued ALN QW  placebo injection SC Q6M or DMAb SC
Q6M  QW placebo tablet. At study conclusion, subjects completed a 34-item ques-
tionnaire. Pre-determined endpoints of preference and satisfaction were measured by 
asking subjects to choose the tablet, the injection, or neither, in response to questions 
on preference (“Which do you prefer?”) and satisfaction (“With which frequency of 
administration have you been more satisﬁ ed?”). RESULTS: The subjects (n  251 ALN,
n  253 DMAb) had a mean age of 67.6 years and a median length of prior bisphos-
phonate use of 36 months (range 6 to 192). 483 (95.8%) women took the questionnaire
(240-ALN, 243-DMAb). Of the subjects who responded to the question on preference 
(240-ALN, 240-DMAb) or satisfaction (237-ALN, 242-DMAb), signiﬁ cantly more 
subjects preferred a 6-month injection vs. a weekly oral tablet (ALN:66%-Q6M injec-
tion, 19%-QW tablet, 15%-neither, p  0.0001; DMAb:70%-Q6M injection, 19%-
QW tablet, 12%-neither, p  0.0001) and signiﬁ cantly more subjects reported greater 
satisfaction with the frequency of 6-month vs. weekly dosing (ALN:68%-Q6M injec-
tion, 19%-QW tablet, 14%-neither, p  0.0001; DMAb:70%-Q6M injection, 16%-
QW tablet, 14%-neither, p  0.0001). CONCLUSIONS: A preference for and a greater 
satisfaction with a 6-month injection vs a weekly oral tablet was demonstrated in sub-
jects previously receiving and tolerating ALN therapy.
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COMBINING THE SF–36 PHYSICAL FUNCTION SCALE AND THE
HEALTH ASSESSMENT QUESTIONNAIRE TO IMPROVE MEASUREMENT
OF PHYSICAL FUNCTION RHEUMATOID ARTHRITIS (RA): RESULTS: 
FROM THE PREMIER STUDY
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OBJECTIVES: RA clinical studies using the SF-36 Physical Function (PF) scale and 
Health Assessment Questionnaire (HAQ) have identiﬁ ed limitations in each instru-
ment’s sensitivity across the full range of disease severity. Item Response Theory (IRT) 
estimates were used to develop a composite of both instruments (PF–HAQ) to provide
a more sensitive measure of physical health. METHODS: Data for 799 patients from
a 2-year randomized control study of adalimumab in early RA (3 years) were 
employed. Patients received adalimumab plus methotrexate; adalimumab monother-
apy; or methotrexate monotherapy. Composite PF–HAQ scores were compared indi-
vidually with PF and HAQ using 1) comparison of ﬂ oor and ceiling effects; 2) 
ANCOVA models with ACR criteria classiﬁ cation or treatment as factors (covariates: 
sex, age, BMI); and 3) receiver operating characteristics (ROC) analyses using ACR50
criteria as a gold standard. RESULTS: At baseline, 6.2% of patients were at ﬂ oor for
the PF. At endpoint, 37.7% and 14.2% of HAQ and PF scores, respectively, were at
ceiling. IRT scores, by deﬁ nition, have no ceiling or ﬂ oor. Signiﬁ cant differences across
treatment groups were obtained (F [2526]  12.21, 7.48, 3.02, p  0.001 for all com-
parisons). PF–HAQ had signiﬁ cantly more power than either individual scale to detect 
treatment differences (F-statistic ratios of PF–HAQ with PF and HAQ were 1.6 and 
4.0, respectively). PF–HAQ was better than PF at detecting differences in endpoint
ACR criteria (F-statistic ratio for PF–HAQ to PF was 1.28). ROC analyses indicated 
that PF–HAQ provided better measurement precision (p  0.001) vs. PF and equiva-
lent/better precision vs. HAQ (p  0.14) (AUC: PF 0.80, 95% CI: 0.79–0.81; HAQ: 
0.83 [0.82–0.85]; PF–HAQ: 0.84 [0.83–0.85]). CONCLUSIONS: Combining PF and 
HAQ measures into a single measure eliminated ﬂ oor/ceiling effects, and provided 
greater efﬁ ciency in discriminating treatment effects, as well as greater sensitivity vs. 
common diagnostic criteria.
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OBJECTIVES: To assess the impact of compliance with biologic therapies on clinical
measures, including symptoms, quality of life (QOL), and medical resource use in 
rheumatoid arthritis (RA) patients. METHODS: Patient-reported data were collected
from the 2008 Rheumatoid Arthritis Patient Study, an Internet survey of RA patients. 
Clinical measures and medical resource use (number of surgeries, emergency room 
and physician visits, and hospitalizations within six months) were compared among 
three groups: patients who used biologics before but discontinued; patients who cur-
rently use biologics but skipped doses within the last 12 months; and patients who 
currently use biologics without skipping. Symptoms included morning stiffness, 
fatigue, and pain scores measured on a Likert scare from zero (no symptoms) to 10 
(severe symptoms). QOL was measured by the mental component summary (MCS) 
and physical component summary (PCS) of the Health Survey Short Form (SF-36).
RESULTS: Of 2,048 respondents, 475 (23.2%) used biologic therapies, 74.3% were
female, and the average age was 51.9 years. The average duration of RA was 11.9
years, with 20.0% reporting severe disease. Among patients who used biologics, 148
(31.2%) patients discontinued and 80 (16.8%) patients reported skipping doses in the
last 12 months. Compared to the groups who discontinued, or skipped biologic doses, 
the current users who did not skip had the best symptom and QOL scores: morning 
stiffness (6.51, 5.91, 5.77), fatigue (7.00, 6.96, 6.23), pain (6.51, 6.18, 5.71), MCS
(38.0, 41.7, 41.9), and PCS (30.4, 29.2, 32.8) (all P  0.05). There were no statistical 
differences in medical resource use except physician visits, which were signiﬁ cantly 
lower in current users who did not skip doses. CONCLUSIONS: Patients who were 
compliant with their biologic therapy had better outcomes compared with patients
who discontinued or skipped doses. Compliance with biologic therapy is an important
factor optimizing effective treatment of RA.
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OBJECTIVES: Methods have been well-established to estimate the excess amount of 
health care services and work loss costs of RA and, to a lesser extent, caregiver costs. 
To estimate the comprehensive societal cost of RA, we assessed intangible costs associ-
ated with functional disability/quality of life and mortality legal system jury award
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data from the United States. METHODS: We obtained data on jury awards for injuries
that caused functional disabilities similar to RA. We identiﬁ ed a sample of jury awards 
involving limb disabilities and/or losses. With these award amounts, we computed the
average jury award and calculated its annuity equivalence, assuming an average US
life expectancy. For RA-associated early mortality, we employed data from the medical 
literature to compute the difference between the present value of sex-speciﬁ c lifetime
earnings of RA patients, with adjustments to reﬂ ect reduced life expectancy and 
average lifetime earnings in the United States. Tangible costs associated with RA 
(e.g., health care, workplace, paid/unpaid help, government disability) were derived 
from private insurance, Medicare, and Medicaid claims databases; disability and
medical absence data; and the literature. Patient-level cost estimates were weighted by 
the prevalence of relevant populations to compute societal costs (2005 US dollars).
RESULTS: The average annuity per jury award for injuries similar to RA disabilities 
was $55,700. This corresponds to an annual societal value of disability/QOL deterio-
ration of $10.8 billion. The annualized reduction in lifetime earnings per RA patient
(vs. those without RA) was $7,420, or $9.6 billion in total. Thus, the annual intangible 
costs of functional disability/QOL and mortality totaled $20.4 billion. Total tangible
societal costs were $19.3 billion ($8.4 billion for direct costs [patient health care]; and 
$10.9 billion for indirect costs [other RA consequences]). CONCLUSIONS: Including 
intangible costs increased the annual societal costs of RA by $20.4 billion in the United
States, for a total of $39.7 billion.
PODIUM SESSION IV: QUALITY OF LIFE & UTILITY STUDIES
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COMPARISON BETWEEN THE EQ–5D AND THE SEVEN DERIVED
HEALTH UTILITIES IN STROKE PATIENTS USING A NATIONAL
REPRESENTATIVE SAMPLE IN THE UNITED STATES
Nichol MB, Wu J, Gu NY
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OBJECTIVES: 1) To assess the associations of EQ-5D index score, EQ-VAS, and seven
estimated utilities with self-reported stroke in a U.S. national representative sample, 
and 2) To compare estimated utilities with EQ-5D and EQ-VAS in both stroke and 
non-stroke samples. METHODS: Data were extracted from the 2001 Household
Component of the Medical Expenditure Panel Survey(MEPS). Seven estimated utilities 
were derived from the SF-12v1, including HUI3/VAS item models(IM) and categori-
cal models(CM) from the Sengupta-Nichol, Brazier SF-6D, Lundberg VAS, and Sullivan 
EQ-5D algorithms. An analysis of covariance was used to determine differences in 
mean utility scores between individuals with and without stroke. Covariate(social-
demographic and comorbidity) adjusted effect sizes(ES) were calculated for utilities
between individuals with and without stroke, as well as between estimated utilities and
EQ-5D/EQ-VAS. RESULTS: A total of 19,475 individuals completed SF-12v1, EQ-
5D, and EQ-VAS. Mean age was 42.2 years, 40% were female, 14% had self-reported 
stroke. Individuals with stroke had signiﬁ cantly lower covariate adjusted mean EQ-5D
(0.16 points difference), EQ-VAS (0.14 points difference), and estimated utilities (0.11
or 0.12 points differences) when compared to those without stroke(all p  0.0001). 
Stroke individuals showed large effect in utility scores when compared to non-stroke
individuals. HUI3-IM (ES  1.20) and HUI3-CM (ES  1.22) showed ES similar to 
EQ-5D (ES  1.23), and both VAS-IM and VAS-CM (ES  1.09) had ES similar to 
EQ-VAS (ES  1.08). When comparing estimated utilities with EQ-5D, Sullivan EQ-5D 
(ES  0.26) and SF-6D(ES  0.29) showed small effect, while other estimated utilities
showed no effect in stroke individuals; all estimated utilities showed small (ES  0.23
for Sullivan EQ-5D) to large effect (ES  1.00 for SF-6D) in non-stroke individuals.
CONCLUSIONS: EQ-5D, EQ-VAS and estimated utilities in stroke individuals dis-
played clinical meaningful differences from those without stroke. Derived HUI3/VAS
showed the similarity with the EQ-5D/EQ-VAS in stroke individuals. Our ﬁ ndings
indicated that EQ-5D, EQ-VAS, and estimated HUI3 and VAS were sensitive to health
state and could be used for cost-effectiveness analysis in stroke individuals.
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DEVELOPMENT OF AN ITEM BANK FOR A COMPUTER ADAPTIVE
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OBJECTIVES: To establish an item bank for Computer Adaptive Measure of Func-
tional Cognition for Stroke (CAMFC-S). The prerequisite for monitoring the effective-
ness of pharmaceutical interventions for stroke-related cognitive deﬁ cits is the
development of reliable and valid cognitive measures. Existing measures of post-stroke 
cognition: 1) are few in number; 2) lack precision and efﬁ ciency for stroke; and 3) fail 
to reﬂ ect cognitive functioning that is related to everyday activities (i.e., “functional 
cognition”). METHODS: A total of functional cognition items across 10 domains 
(Language, Reading/Writing, Numeric Calculation, Limb Praxis, Visuospatial Func-
tion, Social Use of Language, Emotional Function, Attention, Memory, and Executive
Function) were administered to 128 individuals with stroke 49 acute (7–21 days post
onset) and 79 chronic (83–372 days post onset). Rasch and classical test analyses were
performed on 128 self-report ratings and 124 caregiver ratings. Neuropsychological
testing was performed with 62 randomly selected patients. RESULTS: Conﬁ rmatory 
factor analysis of each domain supported both unidimensionality and hypothesized
multidimensional structures for 5 of 10 domains with 1 domain only supporting a 
multidimensional structure. The all-item measure and separate domain measures 
showed excellent internal consistency (high person separation reliability and high 
Cronbach’s alphas). The all-item measure and domain measures (except Limb Praxis) 
produced expected item-difﬁ culty hierarchical orders. The all-item measure showed 
excellent person separation and except for Limb Praxis and Numeric Calculation 
(patient self-report), domain measures showed good person separation. While the All
Item measure showed no ﬂ oor or ceiling effects 5 of 10 domain measures showed 
ceiling effects. The domain measures showed fair-moderate correlations with analo-
gous neuropsychological test performance. CONCLUSIONS: With the exception of 
Limb Praxis, the ﬁ ndings support developing all-item and domain-speciﬁ c computer 
adaptive tests of functional cognition.
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ESTIMATION OF UTILITY VALUES FOR DIABETES–RELATED
COMPLICATIONS ON QUALITY OF LIFE FOR PATIENTS WITH TYPE–2
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O’Reilly D1, Xie F1, Pullenayegum E1, Gerstein H2, Blackhouse G1, Tarride JE1, Goeree RA1
1McMaster University, Hamilton, ON, Canada, 2McMaster University and Hamilton Health 
Sciences, Hamilton, ON, Canada
OBJECTIVES: The primary aim of this study was to analyze quality of life (QOL) 
data from a Canadian population with type-2 diabetes in order to estimate the impact 
of a number of diabetes-related complications on utility measures of QOL. METHODS:
The EuroQol EQ-5D instrument was administered 1147 patients with type-2 diabetes.
After controlling for age, gender and duration of diabetes, utilities were estimated by
regressing the EQ-5D scores onto binary indicators for the presence of an event. The 
primary method of analysis was Ordinary Least Squares (OLS), and due to concerns 
over non-Normality, bootstrap standard errors (SE) were calculated. Both United
States and UK scoring algorithms were used to estimate respective utility decrements. 
RESULTS: 1,143 participants were included in the analysis. Using the UK algorithm 
and the OLS model, the utility decrements were as follows: myocardial infarction
(MI)  0.081 (SE  0.026), amputation  0.098 (SE  0.090), stroke  0.067 (SE 
 0.036), and kidney failure  0.158 (SE  0.073). The US algorithm produced the
following values: MI  0.059 (SE  0.017), amputation  0.063 (SE  0.059), stroke 
 0.046 (SE  0.023), and kidney failure  0.102 (SE  0.047). Estimates of these 
effects based on both the Tobit and censored least absolute deviations estimator
models were also reported and compared. CONCLUSIONS: This study used various 
regression models to estimate the decrements in EQ5D utility values associated with
several important complications commonly experienced in patients with diabetes. The
most signiﬁ cant impacts on QOL were associated with kidney failure and MI. The
decrements estimated using US scoring algorithm were smaller than using UK scoring 
algorithm. These utility values can be used to assess the outcome of interventions that 
reduce these diabetes-related complications and will have a great impact on future 
economic evaluations of diabetes management strategies in Canada.
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OBJECTIVES: To fully understand the multi-faceted impact of diabetes treatments, 
patients perceptions of health-related quality of life, treatment satisfaction and
treatment behavior must be assessed. Available diabetes patient reported outcome
(PRO) measures are speciﬁ c to type-1 or type-2 diabetes, treatment or delivery 
modality or are not inclusive of all potential impacts. The purpose of this study 
was to validate the Treatment Related Impact Measure (TRIM) for Diabetes and
Diabetes Device which were developed to assess the full range of impacts across 
diabetes type, all current delivery systems and diabetes treatments. METHODS:
The 60 item TRIM-Diabetes/-Device, developed in a prior study according to the
draft FDA guidelines, was validated in a web-based survey for measurement and
psychometric properties (factor structure, reliability, validity) for the total and each 
domain score. RESULTS: A total of 507 respondents completed the web-survey; 24
of 60 items were dropped due to redundancy, ceiling effects, poor factor loadings 
and/or poor conceptual ﬁ t, resulting in a 28 item TRIM-Diabetes and 8 item TRIM-
Device. A ﬁ ve-factor structure for the TRIM-diabetes with domains of treatment 
burden, daily life diabetes management, psychological health and compliance and 2 
domains of device function and device bother for the TRIM-Device were found. 
Internal consistency coefﬁ cients of the total score and each subscale ranged between
0.80 and 0.94 and test-retest reliability ranged from 0.71 to 0.89. All pre-speciﬁ ed 
hypotheses for convergent and known-groups validity were met. The estimated time
for completion of the combined measures is four minutes. CONCLUSIONS: The 
development of these measures has been conducted according to well deﬁ ned scientiﬁ c
principles, suggesting that the total score and each domain subscale, can be considered 
a brief, conceptually sound, rigorously developed PRO measure with strong evidence 
supporting the psychometric properties. Use of these measures in both clinical and 
research setting can facilitate targeted interventions with more positive treatment
outcomes.
